GlassScriptPhysician profile
Nathan Kyle Hill
NPI 1609461805
$3,740.14
in general payments reported to CMS, 2019-2025
14 companies · $542 in 2025
The $542 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,407 · 2022: $407 · 2023: $694 · 2024: $690 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,344.72 | 2021-2025 | Lifevest |
| Atricure, INC. | $1,037.26 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $323.96 | 2021-2024 | |
| Pfizer INC. | $276.03 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $143.89 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $124.90 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device, Emblem Mri S-Icd |
| Medtronic, INC. | $116.15 | 2022-2023 | Mycarelink, Linq II |
| Chiesi USA, INC. | $97.28 | 2023-2025 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $93.17 | 2024-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $84.63 | 2023-2024 | Wainua, Farxiga, Brilinta |
| Cvrx, INC. | $41.13 | 2022-2024 | Barostim Neo System |
| Novo Nordisk INC | $21.49 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $20.02 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.